Pharmaceuticals Australia

Australia RSV Vaccines Market Analysis, 2024–2034

Australia RSV Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Product, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Australia · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $42.2 Mn Estimated value
Estimate 2025 $47.9 Mn 1.1% of the global market
Projected 2034 $149.8 Mn 212.6% Adds $101.9 Mn over 9 forecast years
CAGR 2025–2034 13.5% Faster than 68% of 180 Pharmaceuticals markets here
Key players 5
  • Australia is 1.09% of the global market.
  • In APAC, the largest is China at $306.6 Mn.
  • Fastest growing: India at 14.6% a year.
  • Australia ranks 5th of 10 by size in APAC.

Market size projection

Australia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$101.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
RSV Vaccines Market market size by year, Australia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $42.2 Mn — —
2025 (base) $47.9 Mn +$5.7 Mn —
2026 (forecast) $54.4 Mn +$6.5 Mn +13.5%
2027 (forecast) $61.7 Mn +$7.3 Mn +28.8%
2028 (forecast) $70.1 Mn +$8.3 Mn +46.2%
2029 (forecast) $79.5 Mn +$9.5 Mn +66%
2030 (forecast) $90.3 Mn +$10.7 Mn +88.4%
2031 (forecast) $102.4 Mn +$12.2 Mn +113.8%
2032 (forecast) $116.3 Mn +$13.8 Mn +142.6%
2033 (forecast) $132.0 Mn +$15.7 Mn +175.4%
2034 (forecast) $149.8 Mn +$17.8 Mn +212.6%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $4.39 Bn
  2. North America $1.91 Bn
  3. US $1.67 Bn
  4. APAC $952.6 Mn
  5. Europe $754.4 Mn
  6. Canada $321.6 Mn
  7. China $306.6 Mn
  8. Japan $246.0 Mn
  9. Middle East $189.0 Mn
  10. Latin America $177.4 Mn
  11. Germany $156.7 Mn
  12. France $122.5 Mn
  13. Brazil $120.7 Mn
  14. UK $112.1 Mn
  15. Italy $114.1 Mn
  16. Spain $88.5 Mn
  17. India $85.4 Mn
  18. Ecuador $81.9 Mn
  19. Africa $75.1 Mn
  20. Saudi Arabia $73.0 Mn
  21. Mexico $66.4 Mn
  22. New Zealand $49.1 Mn
  23. Australia (this report) $47.9 Mn
  24. Russia $41.9 Mn
  25. South Africa $27.5 Mn
  26. UAE $25.3 Mn
  27. Egypt $12.2 Mn
  28. Philippines $10.1 Mn
  29. Hong Kong $7.6 Mn
  30. Malaysia $6.0 Mn
  31. Singapore $5.3 Mn
  32. Thailand $4.7 Mn
  33. Kenya $3.1 Mn

The Australia RSV Vaccines Market Analysis Executive Summary

RSV vaccines protect older adults, pregnant women (for their babies) and infants against respiratory syncytial virus, a common cause of serious chest infections.

Key segments of the RSV Vaccines market include product (Older Adult Vaccines, Maternal Vaccines and Infant Monoclonal Antibodies) and age (Infants, Older Adults and Pregnant Women).

Australia RSV Vaccines Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the RSV Vaccines market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the RSV Vaccines market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the RSV Vaccines market.

Competitive Landscape for RSV Vaccines Market in Australia

The RSV Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for RSV Vaccines Market in Australia

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for RSV Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Australia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in RSV Vaccines right now, from free public sources.

Clinical trials

12 active trials in Australia

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Pfizer Inc. 14 active trials on ClinicalTrials.gov (opens in a new tab)
  2. GSK PLC 6 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Sanofi 5 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Guangzhou Patronus Biotech Co., Ltd. 4 active trials on ClinicalTrials.gov (opens in a new tab)
  5. MAXVAX Biotechnology Limited Liability Company 4 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 397 papers since 2021 (worldwide)

  1. The "ever-vaccinated" stock-flow bias in adult RSV vaccine policy evaluation: A methodological caution and a flow-based remedy. Human vaccines & immunotherapeutics, 2026
  2. Decision-Making About Respiratory Syncytial Virus Immunization for Infants: Qualitative Interview Study. JMIR formative research, 2026
  3. Towards regulatory acceptance of 3D in vitro mucosal models in non-clinical vaccine development and market authorization. NAM journal, 2026
  4. Comparison of Respiratory Syncytial Virus Versus Influenza-Associated Acute Respiratory Illness Hospitalizations Among Adults in North America. Infectious diseases and therapy, 2026
  5. A signal-enhanced competitive ELISA based on peptide screened by solid-liquid phase panning hybrid for sensitive detection of respiratory syncytial virus glycoprotein. Analytica chimica acta, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

RSV Vaccines in context

Australia compared

  • Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 15 countries we cover in APAC.[1]
  • Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 18.1% of people (2025). World: 10.4% of people (2025). 3rd highest of the 16 countries we cover in APAC.[3]

Questions, answered with public data

How many clinical trials on RSV Vaccines are running in Australia?
12 studies are recruiting, active or about to start in Australia.[4]
How much research is published on RSV Vaccines?
PubMed lists 397 papers added since January 2021 that match this market, worldwide.[5]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.

[5] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about RSV Vaccines in Australia? Our analysts can size it for your plan. Talk to us See the public data Measles vaccine for every country, free. Open the Public Health Dashboard

From our blog

Molecular Point-of-Care Tests: Lab Accuracy, Clinic SpeedTB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade… Antimicrobial Resistance: Why Faster Testing MattersDrug-resistant infections already kill over a million people a year. Faster testing helps doctors pick the… Needleless Connectors: Small Device, Big Infection ImpactNeedleless connectors protect staff from needle injuries, but if not cleaned they can let germs into the…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Australia

See all
Same topic, other categories

Related on vaccines and respiratory

See the topic